Clearmind Medicine (NASDAQ: CMND; FSE: CWY0) has announced that it has added Tel Aviv Sourasky Medical Center (TASMC) to the list of clinical sites for its ongoing Phase 1/2a trial evaluating CMND-100—a proprietary MEAI...
Immunic (NASDAQ: IMUX) has announced new, positive long-term open-label extension (OLE) data from its Phase 2 EMPhASIS trial of lead asset, orally available nuclear receptor-related 1 (Nurr1) activator, vidofludimus...
Closely held VeriSIM Life is leveraging multi-disciplinary quantitative methods to predict patient outcomes and accelerate the discovery, development, and commercialization of transformative therapies. The company aims...
Medicus Pharma (NASDAQ: MDCX) has announced the appointment of Andrew Smith as chief operating officer (COO). A seasoned leader in asset management and financial operations with more than three decades of experience, Mr...
Ladenburg Thalmann announced that Kevin DeGeeter has rejoined the firm as a managing director in its equity research department, effective June 2025. In this role, Mr. DeGeeter will lead equity research coverage of...
ArriVent BioPharma (NASDAQ: AVBP) announced encouraging additional follow-up proof-of-concept data from its global Phase 1b FURTHER trial of first-line firmonertinib monotherapy in patients with non-small cell lung...
Compass Pathways (NASDAQ: CMPS) announced that it has achieved the primary endpoint in the first of two ongoing Phase 3 trials evaluating COMP005 psilocybin for treatment-resistant depression (TRD). The ongoing Phase 3...
Firefly Neuroscience (NASDAQ: AIFF) has announced a significant advancement in Alzheimer’s disease research: the company has identified a novel, objective method for measuring and distinguishing between subjective...
Closely held PharmaJet announced that it has signed an agreement with closely held Immuno Cure, a developer of DNA vaccines. Under the agreement, Immuno Cure will use PharmaJet’s Tropis Intradermal (ID) Needle-Free...
Annexon (NASDAQ: ANNX) announced the appointment of Lloyd Clark, MD, as SVP, ophthalmology strategy and innovation. Dr. Clark brings more than 25 years of experience in treating retinal diseases and advancing novel...